BMPR2 mutation and clinical response to imatinib in a case of heritable pulmonary arterial hypertension
PULMONARY CIRCULATION(2024)
Abstract
Bone morphogenetic protein receptor 2 (BMPR2) mutation is the most common gene mutation implicated in the pathogenesis of pulmonary arterial hypertension (PAH). We describe, for the first time, an excellent clinical response to tyrosine kinase inhibitor imatinib in a patient with heritable PAH from BMPR2 mutation.
MoreTranslated text
Key words
Bmpr2 mutation,hereditary,imatinib,pulmonary hypertension
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined